Is intra-cellular therapies a buy?
Intra-Cellular Therapies has received a consensus rating of Buy. The company’s average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
What does intra-cellular therapies inc do?
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders.
Where is Intracellular Therapies located?
Locations
| Country | City | Address |
|---|---|---|
| United States | New York | 430 E 29th St #900 HQ |
Is Itci a good stock to buy?
The consensus among 6 Wall Street analysts covering (NASDAQ: ITCI) stock is to Strong Buy ITCI stock.
Should I buy Itci stock?
The financial health and growth prospects of ITCI, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Who owns Intra-Cellular Therapies?
Sharon Mates, Ph. (ITCI), Dr. Mates leads Intra-Cellular Therapies, a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative drugs that address underserved medical needs in complex psychiatric and neurologic diseases.
How many employees does Intra-Cellular Therapies have?
Intra-Cellular Therapies total number of employees in 2021 was 512, a 33.68% increase from 2020. Intra-Cellular Therapies total number of employees in 2020 was 383, a 16.06% increase from 2019. Intra-Cellular Therapies total number of employees in 2019 was 330, a 352.05% increase from 2018.
Who manufactures Caplyta?
(Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration ( FDA ) for the treatment of schizophrenia in adults.
When did intra cellular therapies go public?
March 5, 2015
Intra-Cellular Therapies Prices $114 Million Public Offering of Common Stock. NEW YORK , March 5, 2015 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc.
Who owns Caplyta?
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults | Intra-Cellular Therapies Inc.
Is intra FDA approved?
A. As a dietary supplement, Intra is considered a food, and does not require FDA approval. The FDA does not offer opinions on or approval of dietary supplements. Extensive and stringent independent laboratory testing confirms the safety and purity of all components of Intra.
Who owns intra cellular therapies?
Who owns intra-cellular therapies?
Is intra safe?
Intra is a very safe balanced formulation with no single herbal extract present at high levels. There are no ingredients found in Intra that would prohibit pregnant or nursing women from taking 28 ml of Intra a day.
What is the benefit of intra supplement?
As a natural food supplement intra helps balance and strengthen the body’s systems with the essential nutrients that are lacking in most modern diets. Intra contains herbs that help to protect the body from our toxic environment. It provides a high level of antioxidants that help maintain youthful vitality.
What is the side effects of Intra?
Side Effects of Intra are Nausea, Common cold, Cough, Blurred vision, Menstrual disorder.
Is Intra a good supplement?
In general, Intra helps support and strengthen the areas of the body where we are weakest – often the results are very dramatic. Everyone who uses Intra daily will experience different benefits. Has the safety of Intra been proven by any type of laboratory testing? Yes, Intra has undergone an LD50 Test.
Is Intra lifestyle FDA approved?
Is Intra safe?